Mazar AP - Search Results

1

Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.

Hansen AP, Petros AM, Meadows RP, Nettesheim DG, Mazar AP, Olejniczak ET, Xu RX, Pederson TM, Henkin J, Fesik SW. Hansen AP, et al. Among authors: mazar ap. Biochemistry. 1994 Apr 26;33(16):4847-64. doi: 10.1021/bi00182a013. Biochemistry. 1994. PMID: 8161544

2

A practical method for uniform isotopic labeling of recombinant proteins in mammalian cells.

Hansen AP, Petros AM, Mazar AP, Pederson TM, Rueter A, Fesik SW. Hansen AP, et al. Among authors: mazar ap. Biochemistry. 1992 Dec 29;31(51):12713-8. doi: 10.1021/bi00166a001. Biochemistry. 1992. PMID: 1463742

3

Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin).

Wang J, Mazar A, Quan N, Schneider A, Henkin J. Wang J, et al. Eur J Biochem. 1997 Jul 1;247(1):256-61. doi: 10.1111/j.1432-1033.1997.00256.x. Eur J Biochem. 1997. PMID: 9249034 Free article.

4

Domain structure and interactions of recombinant urokinase-type plasminogen activator.

Novokhatny V, Medved L, Mazar A, Marcotte P, Henkin J, Ingham K. Novokhatny V, et al. J Biol Chem. 1992 Feb 25;267(6):3878-85. J Biol Chem. 1992. PMID: 1310986 Free article.

5

Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.

Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. Rabbani SA, et al. Among authors: mazar ap. J Cell Physiol. 1997 Aug;172(2):137-45. doi: 10.1002/(SICI)1097-4652(199708)172:2<137::AID-JCP1>3.0.CO;2-P. J Cell Physiol. 1997. PMID: 9258335

6

An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.

Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D. Rabbani SA, et al. Biochem Biophys Res Commun. 1990 Dec 31;173(3):1058-64. doi: 10.1016/s0006-291x(05)80893-9. Biochem Biophys Res Commun. 1990. PMID: 2125213

7

Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1.

Higazi AA, Mazar A, Wang J, Reilly R, Henkin J, Kniss D, Cines D. Higazi AA, et al. Blood. 1996 May 1;87(9):3545-9. Blood. 1996. PMID: 8611676 Free article.

8

Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.

Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, Goltzman D. Rabbani SA, et al. Among authors: mazar ap. J Biol Chem. 1992 Jul 15;267(20):14151-6. J Biol Chem. 1992. PMID: 1321137 Free article.

9

Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).

Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. Rabbani SA, et al. Among authors: mazar ap. Int J Cancer. 1995 Dec 11;63(6):840-5. doi: 10.1002/ijc.2910630615. Int J Cancer. 1995. PMID: 8847143

10

The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.

Mazar AP, Henkin J, Goldfarb RH. Mazar AP, et al. Angiogenesis. 1999;3(1):15-32. doi: 10.1023/a:1009095825561. Angiogenesis. 1999. PMID: 14517441

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters